This paper was dated 21 January, 2010, two years ago, wondering if there is some new development on the same subject?

At the top of the NYT article it gives a date of 2/1/12. This was also listed in Googlenews, so I don't think it's two years old.

I think WXXU was referring to the journal article posted by GerryW;that is dated 1/21/10.

The immune response we have may a way to end these diseases. Affiris, an Austrian biotech, is beginning Phase II trial on a vaccine for prevention of AD. Glaxo-Smith Kline is partnering with them to develop the vaccine and has agreed to pay up to $420 million Euro if vaccine goes to market. That seems like a huge vote in confidence, to me at least.


Fierce Vaccines

In October 2011, Affiris announced they would receive funding on a PD vaccine from MJFF. The PD vaccine uses same technology as the AD one, so safety has already been established. I just hope it won't take the typical 14 years before we see any benefit on a large scale.

University of Nebraska researchers are also pursuing a PD vaccine.

In early stages of PD, a vaccine may halt disease progress plus alleviate symptoms. For later disease, it would at very least slow progression.